

Supplemental Table S1. Summary of Main Baseline Characteristics across the Included Studies

Study	Study type	Country	Setting of DPP-4i use	No. of participants/ subjects with diabetes mellitus	DPP-4i users/non-DPP-4i users	Mortality	RAS blocker use among DPP-4i users	Metformin use among DPP-4i users
Chen et al. (2020) [16]	Observational	China	Outpatient	904/120	20/100	5/20 vs. 14/100	32/120	43/120
Fadini et al. (2020) [14]	Observational	Italy	Outpatient	403/85	9/76	1/9 vs. 10/76	37/85	27/85
Israelsen et al. (2021) [10]	Observational	Denmark	Outpatient	NA/996	284/644	30/284 vs. 21/644	NR	NR
Mirani et al. (2020) [13]	Observational	Italy	Outpatient	387/90	11/79	1/11 vs. 37/79	40/90	69/90
Noh et al. (2021) [9]	Observational	South Korea	Outpatient	NA/586	453/133	47/453 vs. 22/133	NR	NR
Perez-Belmonte et al. (2021) [12]	Observational	Spain	Outpatient	NA/2,666	791/1,875	75/180 vs. 440/1,409	NR	NR
Silverii et al. (2021) [17]	Observational	Italy	Outpatient	NA/159	13/146	5/13 vs. 54/146	NR	NR
Solerte et al. (2020) [8]	Observational	Italy	Inpatient	NA/338	169/169	31/169 vs. 63/169	38/169 vs. 29/169	79/169 vs. 63/169
Wargny et al. (2021) [15]	Observational	France	Outpatient	NA/2,796	615/2,181	113/615 vs. 464/2,179	NR	NR
Zhou et al. (2020) [11]	Observational	China	Inpatient	NA/444	111/333	2/11 vs. 11/333	NR	NR

DPP-4i, dipeptidyl-peptidase-4 inhibitor; RAS, renin-angiotensin system; NA, not applicable; NR, not reported.